Drugs
Drug and therapeutic reference pages — a comprehensive view: mechanism, targets, indications, clinical trials, ADMET, adverse events, and many more.
4701 drugs in the atlas
Featured drugs
Looking for a specific drug? Use the search on the home page.
Afatinib
Summary Afatinib (CHEMBL1173655) is an approved small-molecule tyrosine kinase inhibitor (ATC L01EB03) targeting EGFR and ERBB2; indicated across 30 conditions including neoplasm and head and neck …
→Aspirin
Summary Aspirin (CHEMBL25) is an approved small-molecule non-steroidal anti-inflammatory drug (ATC B01AC06) targeting PTGS1, PTGS2, and ASIC3; indicated across 167 conditions including stroke disorder …
→Axitinib
Summary Axitinib (CHEMBL1289926) is an approved small-molecule antineoplastic agent (ATC L01EK01) targeting KDR and PLK4; indicated across 51 conditions including neoplasm and renal cell carcinoma; …
→Bosutinib
Summary Bosutinib (CHEMBL288441) is an approved small-molecule antineoplastic agent (ATC L01EA04) targeting CAMK2G, ABL1, and CAMK1D; indicated across 20 conditions including neoplasm and chronic …
→Cisplatin
Summary Cisplatin (CHEMBL11359) is an approved small molecule (ATC L01XA01); indicated across 195 conditions including neoplasm and head and neck squamous cell carcinoma; with CIViC clinical evidence …
→Dasatinib Anhydrous
Summary Dasatinib Anhydrous (CHEMBL1421) is an approved small-molecule antineoplastic agent (ATC L01EA02) targeting ABL1, SIK1, and SIK2; indicated across 87 conditions including chronic myeloid …
→Dexamethasone
Summary Dexamethasone (CHEMBL384467) is an approved small-molecule immunosuppressive agent (ATC A01AC02) targeting NR1I2, NR3C1, and NR3C2; indicated across 315 conditions including eye disorder and …
→Erlotinib
Summary Erlotinib (CHEMBL553) is an approved small-molecule antineoplastic agent (ATC L01EB02) targeting SLCO2B1 and EGFR; indicated across 68 conditions including neoplasm and head and neck squamous …
→Everolimus
Summary Everolimus (CHEMBL1908360) is an approved small-molecule antineoplastic agent (ATC L01EG02) targeting MTOR; indicated across 147 conditions including breast carcinoma and renal cell carcinoma; …
→Fluorouracil
Summary Fluorouracil (CHEMBL185) is an approved small-molecule antineoplastic agent (ATC L01BC02); indicated across 114 conditions including actinic keratosis and neoplasm; with CIViC clinical …
→Gefitinib
Summary Gefitinib (CHEMBL939) is an approved small-molecule antineoplastic agent (ATC L01EB01) targeting EGFR; indicated across 51 conditions including non-small cell lung carcinoma and neoplasm; with …
→Gemcitabine
Summary Gemcitabine (CHEMBL888) is an approved small-molecule antineoplastic agent (ATC L01BC05) targeting RRM1 and RRM2; indicated across 114 conditions including neoplasm and exocrine pancreatic …
→Imatinib
Summary Imatinib (CHEMBL941) is an approved small-molecule tyrosine kinase inhibitor (ATC L01EA01) targeting DDR1, DDR2, and ABL1; indicated across 52 conditions including acute lymphoblastic leukemia …
→Methotrexate
Summary Methotrexate (CHEMBL34259) is an approved small-molecule antineoplastic agent (ATC L04AX03) targeting SLC19A1 and SLC46A1; indicated across 164 conditions including rheumatoid arthritis and …
→Nilotinib
Summary Nilotinib (CHEMBL255863) is an approved small-molecule antineoplastic agent (ATC L01EA03) targeting DDR1, DDR2, and ABL1; indicated across 27 conditions including neoplasm and chronic myeloid …
→Olaparib
Summary Olaparib (CHEMBL521686) is an approved small-molecule antineoplastic agent (ATC L01XK01) targeting PARP1, PARP2, and PARP3; indicated across 77 conditions including neoplasm and ovarian …
→Paclitaxel
Summary Paclitaxel (CHEMBL428647) is an approved small-molecule antineoplastic agent (ATC L01CD01) targeting TLR4, TUBB, and NR1I2; indicated across 169 conditions including breast carcinoma and …
→Palbociclib
Summary Palbociclib (CHEMBL189963) is an approved small-molecule EC 2.7.11.22 (cyclin-dependent kinase) inhibitor (ATC L01EF01) targeting CDK4 and CDK6; indicated across 53 conditions including breast …
→Regorafenib
Summary Regorafenib (CHEMBL1946170) is an approved small-molecule antineoplastic agent (ATC L01EX05) targeting KDR and BRAF; indicated across 41 conditions including colorectal adenocarcinoma and …
→Ruxolitinib
Summary Ruxolitinib (CHEMBL1789941) is an approved small-molecule antineoplastic agent (ATC D11AH09) targeting JAK1, JAK2, and JAK3; indicated across 66 conditions including neoplasm and primary …
→Sirolimus
Summary Sirolimus (CHEMBL413) is an approved small-molecule immunosuppressive agent (ATC S01XA23) targeting FKBP1A; indicated across 158 conditions including neoplasm and eye disorder; with CIViC …
→Sorafenib
Summary Sorafenib (CHEMBL1336) is an approved small-molecule antineoplastic agent (ATC L01EX02) targeting PDGFRB, KIT, and FLT3; indicated across 84 conditions including neoplasm and hepatocellular …
→Trametinib
Summary Trametinib (CHEMBL2103875) is an approved small-molecule EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor (ATC L01EE01) targeting MAP2K1 and MAP2K2; indicated across 52 conditions …
→Vemurafenib
Summary Vemurafenib (CHEMBL1229517) is an approved small-molecule antineoplastic agent (ATC L01EC01) targeting BRAF and RAF1; indicated across 22 conditions including melanoma and metastatic melanoma; …
→Sugi Atlas has 4701 drugs in total. The full set is indexable by AI agents and search engines via the sitemap; most users will find a specific drug fastest via the search.